FDA Approves Hologic's Cervista High Throughput Automation System for Cervical Cancer Screening

Hologic, Inc.

, announced today that the U.S. Food and Drug Administration has approved its Cervista HTA system for use with the Company's previously approved Cervista human papillomavirus HR test. The Company's HPV HR test utilizes Hologic's proprietary Invader technology to detect 14 high risk types of HPV that are associated with cervical cancer and precancerous lesions.